Koichiro Kinugawa

Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Background Fulminant myocarditis can result in persistent severe left ventricular dysfunction and complete atrioventricular block (AVB), necessitating cardiac resynchronisation therapy (CRT). However, direct CRT implantation can be sometimes challenging in the context of intensive mechanical circulatory support and systemic steroid therapy, where the risks of procedure-related bleeding and infection are significantly heightened. Case summary This report describes a 64-year-old woman with fulminant myocarditis, severe left ventricular dysfunction, and persistent complete AVB, who was initially managed with extracorporeal membrane oxygenation and the Impella 5.5, along with temporary pacing. Due to the high risks of infection and bleeding, we implanted a leadless pacemaker (Micra AV system) as a temporary measure prior to CRT. Following Micra AV implantation, temporary pacing was successfully removed, and signs of infection and bleeding tendency improved. CRT was subsequently implanted, and Impella 5.5 was successfully weaned. Discussion This case underscores the potential utility of a leadless pacemaker as a bridge to CRT therapy in patients with high risks of bleeding and infection. By employing this approach, the patient’s clinical condition can be optimized, enabling the safe implantation of CRT. Further studies are warranted to validate our findings and evaluate the applicability of our novel strategy.

Year:

2025

Aims The mechanisms underlying very late-onset atrial fibrillation (AF) recurrence, defined as occurring more than 1 year after catheter ablation, are hypothesized to differ from those responsible for recurrence within the first year; however, this remains uncertain. Methods and results Two investigations were conducted in patients undergoing AF ablation. First, non-targeted metabolome analysis was performed in 10 patients with very late-onset recurrence and 10 without recurrence. Second, based on metabolomic findings implicating autophagy, serum levels of the autophagy-related proteins Parkin, a marker of mitophagy, and ATG5, an indicator of bulk autophagy, were measured using ELISA. Associations between these variables and very late-onset recurrence were analysed. Among the 203 patients (mean age 70 years, 63% male), 16 experienced very late-onset recurrence during a mean follow-up of 954 days. Metabolome analysis identified 255 peaks (177 cations and 78 anions). Principal component analysis revealed a reduction in γ-glutamyl dipeptides, contributors to mitochondrial autophagy, in the recurrence group. A serum Parkin level below the median was independently associated with very late-onset recurrence (hazard ratio 3.82, 95% confidence interval 1.20–12.13, P = 0.023), after adjustment for left atrial diameter and diabetes mellitus. In contrast, ATG5 levels were not significantly associated. Parkin levels did not predict recurrence within the first year (log-rank P = 0.09). Conclusion Reduced serum Parkin levels were independently associated with very late-onset recurrence following AF ablation, suggesting that impaired mitochondrial autophagy may contribute to the pathogenesis of long-term AF recurrence.

Year:

2025

Background Secondary mitral regurgitation (SMR) is a major comorbidity in patients with heart failure with reduced ejection fraction (HFrEF). Transcatheter edge-to-edge repair (TEER) using the MitraClip™ system is a promising tool for selected patients with SMR and HFrEF. Durable success using this system in patients who have advanced heart failure and unsuitable anatomy remains a clinical challenge. Case summary Three patients aged 67–72 years with HFrEF on inotropic support successfully underwent Impella®-assisted TEER at our centre. Following the procedure, two patients were able to be weaned off inotropic support and were discharged, while one patient expired during the index hospitalization. Discussion Impella®-assisted TEER may be a feasible strategy for patients with SMR and HFrEF with unstable haemodynamics particularly when cardiac replacement therapy is not applicable.

Year:

2022

Collaborators (2)

Naoya Kataoka

National Institute of Advanced Industrial Science and Technology (AIST)

JAPAN
View details

Teruhiko Imamura

University of Toyama

JAPAN
View details